Despite advances in the practice of living donor liver transplantation (LDLT), the optimum surgical approach with respect to the middle hepatic vein (MHV) in right lobe LDLT remains undefined. We designed a randomized trial to compare the early postoperative outcomes in recipients and donors between extended right lobe grafts (ERGs; transection plane was maintained to the left of MHV and division of MHV performed beyond the segment VIII vein) and modified right lobe grafts (MRGs; transection plane was maintained to the right of MHV; the segment V and VIII drainage was reconstructed using a conduit of recipient portal vein). Eligible patients (n 5 86) were prospectively randomized into the ERG arm (n 5 43) and the MRG arm (n 5 43) at the beginning of donor hepatectomy. The primary endpoint considered in this equivalence trial was patency of the MHV or the reconstructed "neo-MHV" in the recipient. The secondary endpoints included biochemical parameters, postoperative complications, mortality in recipients as well as donors and volume regeneration of remnant liver in donors, measured at 2 months. The patency of the MHV was comparable in the ERG and MRG arms (90.7% versus 81.4%; difference, 9.3%; 95% confidence interval [CI], -5.8 to 24.4; z score, 1.245; P 5 0.21). Volume regeneration of the remnant liver in donors was significantly better in the MRG arm (111.3% versus 87.3%; mean difference, 24%; 95% CI, 14.6-33.3; P < 0.001). The remaining secondary endpoints in donors and recipients were similar between the 2 arms. To conclude, MRG with reconstructed neo-MHV has comparable patency to native MHV in ERG and confers equivalent graft outflow in the recipient. Furthermore, it allows better remnant liver regeneration in the donor at 2 months.
graft but its outflow too is equally vital. (1, 2) Inadequate outflow can result in decreased portal flow to the affected areas, resulting in impaired hepatocyte function and regeneration. (3) With respect to right lobe grafts, the middle hepatic vein (MHV) forms a major outflow channel to varying proportions of segments IV, V, and VIII. On the basis of this, 3 types of right lobe grafts can be harvested. The initial practice involved harvesting the right lobe without the MHV. (4) This led to a variable degree of congestion in segments V and VIII, which made the recipient more vulnerable to graft dysfunction. (5) In order to prevent this, the surgical technique was modified to keep the MHV with the right lobe graft, known as the extended right lobe graft (ERG). (6) However, this technique increased the possibility of congestion to segment IV of the remnant liver, which potentially aggravated the risk of liver dysfunction in the donor. (7, 8) In order to circumvent both these Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; CT, computed tomography; EAD, early allograft dysfunction; ERG, extended right lobe graft; GRWR, graft-to-recipient weight ratio; HU, Hounsfield units; ICU, intensive care unit; INR, international normalized ratio; IQR, interquartile range; IV A, cranial part of segment IV; LDLT, living donor liver transplantation; LFT, liver function tests; LHV, left hepatic vein; LSAI, liver-to-spleen attenuation index; MDCT, multiple detector row computed tomography; MELD, Model for EndStage Liver Disease; MHV, middle hepatic vein; MRG, modified right lobe graft; PHLD, posthepatectomy liver dysfunction; PNF, primary nonfunction; RHV, right hepatic vein; SFSS, small-for-size syndrome.
problems, the use of modified right lobe grafts (MRGs) was proposed, which entailed harvesting the right lobe without the MHV but reconstructing the venous drainage of the anterior sector and forming a "neo-MHV." (9) The venous reconstruction can be performed using a variety of techniques, including cryopreserved veins, venous conduits harvested from the explant liver, and synthetic grafts. (9) However, the question as to whether the venous drainage provided by the reconstructed neo-MHV will be equivalent to the native MHV remains unanswered. Apart from the major tributaries, there are numerous small veins within the liver parenchyma that drain into the MHV, hence, reconstruction of the major tributaries alone may not avoid graft congestion altogether. In fact, magnetic resonance imaging-based studies have reported congestion of the right anterior sector in 62% of right lobe grafts even after reconstruction of segment V and VIII drainage. (10) Furthermore, questions regarding the patency of the reconstructed veins as well as the impact of MHV harvest on donor morbidity warrant further clarification. (11) Whenever there is a significant concern regarding donor safety, such as borderline residual liver volume or major drainage of segment IV into the MHV, it would be prudent to err on the side of leaving the MHV with the donor. However, in grafts with adequate liver remnant, and with good segment IV drainage (presence of umbilical fissure vein) (12) into the left hepatic vein (LHV), it is not clear whether to leave the MHV with the donor or to harvest it with the graft. In this background, we designed this randomized trial to compare the early postoperative outcomes in recipients and donors between ERGs and MRGs.
Patients and Methods

STUDY DESIGN
All liver donors and recipients over 18 years of age who underwent right lobe LDLT at our institution during the time period between June 2014 and November 2015 were included in the study. Donor and recipient evaluation was performed according to the standard pretransplant protocol, which included blood investigations, triple phase multiple detector row computed tomography (MDCT) of the abdomen, and multidisciplinary evaluation. Consenting donors were considered eligible for inclusion in the study if the liver anatomy as interpreted from triple phase MDCT of the abdomen was suitable for harvesting an ERG. The criteria for this included the following:
1. Estimated future remnant liver of >30%. 2. Adequate drainage from the cranial part of segment IV (IV A) to the LHV (presence of an umbilical fissure vein). (12) 3. Liver-to-spleen attenuation index (LSAI) > 0 Hounsfield units (HU) on a plain computed tomography (CT) scan.
Exclusion criteria included ABO-incompatible grafts, recipient portal vein thrombosis (portal vein was the conduit used for venous outflow reconstruction in the study), proposed graft-to-recipient weight ratio (GRWR) < 0.7%, and predominant venous drainage of segment IV to MHV. The study protocol was approved by the institutional ethical committee prior to recruitment of patients. The trial was registered with the Clinical Trials Registry of India (registration number CTRI/2016/08/007186).
The first arm of the study population consisted of patients in whom the ERG was harvested, and the second arm included those in whom the MRG was taken. Randomization was performed using a computergenerated randomization sequence enclosed in sealed opaque envelopes, which were opened after right lobe mobilization in the donor.
Recipient liver explant was performed with caval preservation and temporary portocaval shunting. Donor hepatectomy was performed simultaneously, without portal clamping. In patients belonging to the ERG arm, the transection plane was maintained to the left of the MHV, and the MHV division was performed beyond the joining of the segment VIII vein. Because the study included only donors with a predominant drainage of segment IV A to the LHV, almost the whole length of the MHV could be harvested. On the bench, the right hepatic vein (RHV) and MHV orifices were joined together. In some cases, if the length of the MHV was insufficient, a small cuff of the recipient portal vein was used to form a single orifice to avoid tension. In patients belonging to the MRG arm, the transection plane was maintained to the right of the MHV. The segment V and VIII veins joining the MHV were divided. All significant veins (>5 mm diameter) were reconstructed using a segment of the recipient portal vein. The main segment V vein was anastomosed end to end with the conduit, whereas the other draining veins of segment V and VIII were anastomosed end to side. The other end of the conduit was joined to the adjacent wall of RHV to form a single orifice, thereby forming the neo-MHV (Fig. 1) . In both the arms, accessory veins, if encountered, were anastomosed separately to the inferior vena cava. Graft implant was performed in the standard manner, starting with the hepatic venous anastomosis, followed by portal vein anastomosis, reperfusion, and arterial anastomosis. Biliary anastomosis was usually performed in a duct-to-duct manner.
The standard perioperative antibiotic prophylaxis consisted of piperacillin-tazobactum and fluconazole. In patients with preoperative positive culture reports, appropriate culture-sensitive antibiotics were administered in the perioperative period. Triple immunosuppression was administered in the postoperative period, consisting of steroids, tacrolimus, and mycophenolate mofetil. Other drugs and supportive medications including N-acetylcysteine, prostaglandin E1 infusion (for 96 hours), and ursodeoxycholic acid (for 3 months) were also administered as per protocol to all patients in both arms. Duplex ultrasound was performed daily for the first 15 days to assess for patency of graft vessels. In cases with suspected vessel occlusion, findings were confirmed with MDCT angiogram. A plain CT scan for the donor was performed at 2 months postoperatively to assess for liver regeneration. Volume regeneration in the remnant donor liver was measured as the percentage increase in the volume of the remnant liver at 60 days after hepatectomy, calculated using CT volumetry.
DEFINITIONS AND TERMINOLOGY
Warm ischemia time was defined as the time period from hepatic arterial clamping in the donor to the time when the effluent via the hepatic veins at the bench became clear. Cold ischemia time was calculated as the period between the time when the effluent via the hepatic veins was clear until the time of reperfusion of the portal vein in the recipient.
PRIMARY ENDPOINT
The primary endpoint of our study was patency of the MHV or the reconstructed neo-MHV in the recipient.
SECONDARY ENDPOINTS
Recipient Parameters
The peak levels of serum bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, and international normalized ratio (INR) over the first 14 postoperative days were compared between the 2 groups. The other recipient parameters compared were early allograft dysfunction (EAD), small-for-size syndrome (SFSS), primary nonfunction (PNF), posttransplant intensive care unit (ICU) stay, and mortality at 90 days after transplantation.
EAD was defined by the presence of 1 or more of the following parameters: serum bilirubin > 10 mg/dL on postoperative day 7, INR 1.6 on postoperative day 7, or AST or ALT 2000 IU/mL within the first 7 postoperative days. (13) SFSS was defined as graft dysfunction, as evidenced by the presence of 2 of the following on 3 consecutive days in the first postoperative week after transplantation excluding technical (arterial occlusion/portal occlusion/outflow occlusion/bile leak), immunological (rejection), and infectious causes: 
Donor Parameters
The peak levels of serum bilirubin, AST, ALT, and INR over the first 14 postoperative days were compared between the 2 groups. The other donor parameters compared were posthepatectomy liver dysfunction (PHLD), postoperative morbidity, volume regeneration of remnant liver at 2 months, and postoperative hospital stay. Postoperative morbidity was graded as per the Clavien-Dindo grading system. (14) PHLD was defined as increased INR and concomitant hyperbilirubinemia on or after postoperative day 5. (15) Volume regeneration in the donor was defined as percentage increase in volume of the remnant liver at 60 days after hepatectomy, calculated using CT volumetry.
STATISTICAL ANALYSIS
The study was designed as an equivalence trial. The primary endpoint of our study was to show whether patency of the reconstructed and native MHVs was comparable. The reported patency of the native MHV in the ERGs is approximately 90%. (16) The reported patency of the reconstructed MHV is highly variable (52%-90%). (11) Hence, it was taken as 65% in our study, allowing an equivalence margin of 25%. At 95% significance level and power of 80%, a minimum sample size of 43 patients (in each arm) was required to exclude an equivalence margin >25% between the 2 arms.
Continuous variables were expressed as mean and standard deviation, and categorical variables were expressed as counts and percentage. The chi-square test was used for comparison of categorical variables between the 2 arms. Differences between the mean of continuous variables were compared using Student t test. If the distribution was not normal, median and interquartile range (IQR) were reported, and the Mann-Whitney U test was performed. Statistical software SPSS, version 11.5 (SPSS Inc., Chicago, IL) was used for conducting the statistical analysis, and all statistical tests were performed at the 2-tailed significance level of 0.05.
Results
A total of 118 LDLTs were performed during the period of study, of which 86 patients were eligible for randomization (Fig. 2) . Forty-three patients each were randomized to the ERG and MRG arms. The recipient/donor demographic characteristics, biochemical parameters, and operative variables were comparable between the 2 arms ( Table 1) .
The primary endpoint considered was MHV patency in the recipient. The median number of segment V veins reconstructed per modified graft was 1 (range, 1-3) and that of segment VIII veins was 1 (range, 1-3). The mean length of the conduit was 61.7 6 6.2 mm. Immediately after reperfusion, none of the patients in either arms of the study showed significant congestion of segment V or VIII. The patency of MHV/neo-MHV was confirmed by on table Duplex scan in all cases. The MHV was patent in 90.7% of patients (39 out of 43 patients) in the ERG arm, and in 81.4% of patients (35 out of 43 patients) in the MRG arm. Hence, the difference in patency rate was 9.3% which was within the equivalence margin and did not reach statistical significance (95% confidence Table 2 ). Four patients in the ERG arm and 8 patients in the MRG arm developed MHV thrombosis. The median posttransplant day of detection of MHV thrombosis was the tenth day in the ERG arm and the ninth day in the MRG arm. The postoperative peak bilirubin, AST, ALT, and INR in these patients were not significantly different between the 2 arms. There was 1 case of EAD in each arm and 1 case of SFSS in the MRG arm (Table 3) . These 3 patients showed segment V/VIII congestion on triple phase CT scan. None of the patients received anticoagulation or underwent radiological/surgical intervention for MHV/neo-MHV thrombosis. However, antiplatelets were started if the platelet count was more than 50,000/mcL. No mortality was encountered among the patients with MHV thrombosis. Among the secondary endpoints considered in the recipient, the peak bilirubin, AST, ALT, INR, and creatinine levels were similar between the 2 arms NOTE: Data are presented as n (%), mean 6 standard deviation, or median (IQR) as appropriate.
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( Table 2 ; Figs. 3 and 4) . Between the ERG and MRG arms, there was no statistically significant difference in the incidence of EAD, SFSS, and PNF. Likewise, there was no significant difference in posttransplant ICU stay or mortality within 90 days between the 2 arms ( Table 2 ). The only case of PNF in our study was a recipient with autoimmune liver disease who received a MRG graft. Although we performed a retransplantation (deceased donor liver transplantation), the patient succumbed to systemic sepsis. With respect to donor parameters between the 2 arms, the postoperative peak liver function tests (LFT), incidence of PHLD, and postoperative hospital stay did not show any difference between the 2 arms (Table 4 ; Figs. 5 and 6). The incidence of postoperative complications was similar between the 2 arms (Table 5 ). However, a mean increase in the volume of the remnant liver was found to be significantly higher in the MRG arm (111.3% versus 87.3%; mean difference, 24%; 95% CI, 14.6-33.3; P < 0.001; Table  4 ).
Discussion
In this randomized trial, we found that there is a significant improvement in remnant liver regeneration in the donor following modified liver graft harvest, wherein the MHV is retained with the remnant liver. The patency rates of the resultant reconstructed MHV in the recipient were similar to the patency rates achieved with the native MHV associated with extended liver graft harvest. There was no significant difference in biochemical parameters, postoperative complications, mortality, and hospital stay of recipients as well as donors between the 2 types of liver grafts studied. Previous nonrandomized comparisons of liver volume regeneration between ERGs and MRGs have reported slightly disparate findings. (17, 18) These studies did not find a significant difference in remnant left liver regeneration in the donor between ERGs and MRGs. Interestingly, they reported a significantly lower regeneration of segment IV in the ERG, which was compensated, however, by exaggerated regeneration of segments II and III. This was attributed to impaired venous drainage and a lesser capacity for regeneration in segment IV. In our study, we did not attempt to discern differences in regeneration capacity between the 2 sectors of the remnant left lobe. It must be borne in mind that in our study, we have excluded donors who had predominant segment IV drainage into MHV. In spite of this, there was a siginificant reduction in volume regeneration in the ERG arm. This suggests that even minor parenchymal veins from segment IV that drain into the MHV play an important role in subsequent remnant liver volume regeneration.
Nevertheless, like in other studies, the difference in the remnant liver regeneration in the donor between the 2 arms did not translate into any significant difference in biochemical parameters or postoperative complications. This may be attributable to the fact that donors, being healthy individuals with normal livers, are able to overcome the insult caused by the loss of outflow of a portion of the remnant liver without adverse outcomes in most cases. However, even this risk may not be worth taking in the donor population, more so if there is no defined benefit in the recipient with this practice. Moreover, because our follow-up was short, the longterm effect of delay in regeneration is unknown. We did not encounter any grade V postoperative complications in the donors, and the incidence of grade I-IV complications and PHLD was comparable between the 2 arms and similar to those reported by previous studies. (19, 20) A retrospective study on 71 donors had reported 2 cases of PHLD, 1 with extended graft and 1 with modified graft. (19) The primary endpoint considered in our study was patency of the reconstructed MHV. We felt that this would provide the most objective assessment of graft outflow status. The biochemical parameters and postoperative outcomes, although seemingly more vital, may however be dependent on multiple factors and may not truly reflect the changes based on the graft outflow alone. In this study, there was no significant difference in patency rates between the native MHV of extended grafts and the neo-MHV of the modified grafts. The neo-MHV patency at 2 weeks was 81% in our study, which was comparable to the reported patency rates from other series. (11) Akamatsu et al. reported that the cumulative 1-and 3-month patency rate of segment V vein was 93% and 70%, respectively, whereas that for segment VIII vein was 94% and 79%, respectively. (20) Another series of 42 cases with the segment V and VIII veins reconstructed had noted an overall patency rate of 90.5%. (9) These numbers would suggest that satisfactory patency rates can be obtained with reconstruction of the outflow of segments V and VIII using a conduit. We used the recipient portal vein as the conduit in all our cases and, hence, cannot comment on other modes of venous reconstruction such as cryopreserved veins and synthetic grafts.
The median day of MHV thrombosis was the ninth day in the MRG arm and the tenth day in the ERG arm. It is interesting that only 3 out of 12 patients with MHV thrombosis developed radiological signs of congestion and biochemical evidence of liver dysfunction. Despite this, the fact that there was no mortality perhaps suggests that the importance of MHV drainage is crucial only in the first postoperative week after transplant. (21) The similar incidence of EAD and SFSS across the 2 arms probably suggests that outflow through the reconstructed MHV is as good as that of native MHV. We encountered 1 case of PNF, which was in the MRG arm. The overall mortality was also comparable between the 2 arms. These findings compare well with existing literature and lead us to the conclusion that ERGs do not confer any significant advantage to the recipient. Hence, leaving the MHV to the donor may be the better alternative because the donor liver tends to regenerate better with an intact outflow to segment IV.
Our study had several limitations. First, the followup period in our study was short. Longer follow-up may have demonstrated differences in outcomes in donors or recipients. A longterm follow-up study in liver donors has reported splenomegaly and low platelet counts after 1 year, (22) although we are not clear whether this occurred due to MHV harvest or not. Second, portal pressure which is claimed to be an important determinant of liver function in LDLT was not measured routinely in our study. Third, we had excluded grafts with predominant drainage of segment IV into MHV. Whether an MRG in such donors would have performed as well as the ERG remains a moot question. However, given the difference in regeneration between the 2 groups in our study, we feel it would be ethically incorrect to subject donors with predominant segment IV drainage to MHV for an ERG harvest. Finally, it is debatable whether a larger sample size would have picked up differences in biochemical parameters or postoperative outcomes between the 2 arms.
In conclusion, MRG with a reconstructed neo-MHV has comparable patency to a native MHV in ERG among recipients and confers equivalent outflow as evidenced by similar occurrence of liver dysfunction, SFSS, ICU stay, and mortality. Moreover, harvesting right lobe grafts without MHV allows better regeneration of donor remnant liver at 2 months. On the basis of this, we now routinely use MRG in preference to ERG for right lobe LDLT.
